ReviewJournal for immunotherapy of cancer2019
Monalizumab: inhibiting the novel immune checkpoint NKG2A.
Thorbald van Hall et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
202 papers cite itlatest 60 shown
this paperpooled ittrialcites it